EDAP TMS SA to Discuss Financial Results for 2024
The global leader in robotic energy-based therapies, EDAP TMS SA (Nasdaq: EDAP), is set to unveil its financial results for the fourth quarter and full year ending December 31, 2024, on an important call scheduled for March 27. This announcement comes as a key moment for the company, highlighting its commitment to transparent communication with investors and stakeholders.
Key Conference Call Information
The financial results presentation will take place before the market opens, with the conference call commencing at 8:30 AM EDT. This call will be led by CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch. They will share insights into the company's performance and future forecasts.
How to Tune In
Participants can join the conference call through the following numbers: for domestic callers, the dial-in is 1-800-225-9448, while international participants can connect at 1-203-518-9708. Be prepared by noting the passcode: EDAP, which will be required for access.
Webcast Details
For those who prefer online access, a live webcast will also be available. This will provide an interactive medium for stakeholders to engage with the presentation and better understand EDAP's strategic direction. The link for the webcast can be accessed through the official company website.
About EDAP TMS SA
EDAP TMS SA has established itself as a pioneering force in the sector of robotic energy-based therapies. The company dedicates its efforts to developing, manufacturing, and promoting minimally invasive medical devices that leverage advanced ultrasound technology. With a focus on innovation, EDAP TMS has introduced leading solutions such as the Focal One® therapy system, which is gaining acceptance among urologists in the treatment of prostate conditions and has the potential for broader applications.
This technology is not just limited to prostate cancer but indicates a growing trend towards expanding its use for a variety of medical conditions. The efficacy and precision of EDAP's therapies underline the commitment to improving patient outcomes through non-invasive procedures.
Company Contacts for Further Information
For any inquiries, stakeholders can reach out to Blandine Confort, who manages Investor Relations and Legal Affairs at EDAP TMS SA, through the contact number +33 4 72 15 31 50 or via email at bconfort@edap-tms.com. Additionally, John Fraunces from LifeSci Advisors can also be contacted at (917) 355-2395 or jfraunces@lifesciadvisors.com for investor-related questions.
Frequently Asked Questions
What does EDAP TMS SA specialize in?
EDAP TMS SA focuses on robotic energy-based therapies and develops advanced medical devices utilizing ultrasound technology for minimally invasive treatments.
When will the financial results be announced?
The financial results for the fourth quarter and full year 2024 will be announced on March 27, before the market opens.
Who will be presenting during the conference call?
The conference call will feature CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch.
How can I participate in the conference call?
To participate, dial 1-800-225-9448 for domestic calls or 1-203-518-9708 for international calls, using the passcode EDAP.
Is there a webcast available for the conference call?
Yes, a webcast will be available for those who prefer to join online. Details will be provided on the company's official website.
